News

BioStem Technologies to Lead Discussions at Wound Care Symposium

BioStem Technologies to Lead Discussions at Wound Care Symposium

BioStem Technologies Takes Center Stage at SAWC Spring Meeting

BioStem Technologies, Inc. (OTC: BSEM) is preparing to make a significant impact at the upcoming Symposium for Advanced Wound Care (SAWC) Spring meeting, where it will proudly co-exhibit with its strategic partner Venture Medical, LLC. This collaboration underscores their joint commitment to innovation in chronic wound care management.

The SAWC is recognized as a leading platform for educating healthcare professionals focused on treating patients with chronic wounds. During this event, BioStem will not only highlight its proprietary BioREtain® technology but will also feature three scientific posters that affirm the efficacy of its advanced allograft portfolio.

Collaborative Innovation in Wound Care

By co-exhibiting with Venture Medical, BioStem aims to spotlight the combined strengths of its leading placental allograft alongside the Venture OneView™ platform. This state-of-the-art platform is designed to simplify the management of patients who require skin substitutes for chronic wound treatment. “Our premier products, AmnioWrap2® and Vendaje AC®, are primarily available through Venture Medical,” shared Jason Matuszewski, CEO of BioStem. “This partnership provides healthcare providers with tools to enhance patient care from insurance verification through treatment, ultimately streamlining the entire care process.”

SAWC Booth Schedule Overview

The BioStem and Venture Medical booth will feature designated times for attendees to interact with key industry stakeholders. Important discussions will include the emerging reimbursement landscape and building a successful mobile wound care practice. Also highlighted will be compelling data supporting the advantages of BioStem’s proprietary BioREtain® technology and how the Venture OneView™ platform benefits providers.

Highlighting Critical Topics

Friday's schedule includes a sponsored breakfast symposium titled Healing Under Pressure: Advancements in Skin Substitutes for Pressure Ulcer Treatment. This critical discussion will address the necessity of advanced wound care technologies in improving outcomes for patients with non-healing chronic wounds. Topics will cover the latest real-world clinical evidence, data collection efforts, practice management strategies, and legislative actions needed to enhance access to treatment.

Scientific Contributions and Insights

BioStem is excited to announce the display of three accepted scientific posters during the conference, each showcasing valuable clinical and scientific research regarding BioStem’s products. These include:

  • Retrospective Analysis of Complicated Diabetic Foot Ulcers: A Comparison of Retention-Processed Placental Membranes and Standard of Care
  • A Case Series for Managing Complicated Diabetic Foot Wounds
  • Preservation of Key Molecular and Stromal Components via Retention Processing

The data presented in these posters aims to demonstrate the favorable outcomes achieved with BioStem’s BioREtain® technology compared to competitive products. Dr. Wendy Weston, Vice President of Research and Development at BioStem, remarked, “We’re committed to investing in evidence that supports the efficacy of our technology.”

About BioREtain® Technology

BioStem’s BioREtain® method is a proprietary processing technique that retains the essential properties of perinatal tissues while preserving the structure and matrix crucial for effective wound treatment. This patented process is gentle and minimally invasive, ensuring the integrity of amniotic tissue, which is vital for optimal healing outcomes.

Fundamentally, BioStem Technologies stands as a beacon of hope in wound care innovation. Each placental allograft is processed at their FDA registered and AATB accredited facility, embodying their commitment to quality and safety.

Connection and Collaboration

BioStem invites the healthcare community to join their distribution list and engage through their social media channels to stay updated on the latest developments. By fostering a community around wound care, BioStem aims to improve practices and outcomes for patients worldwide.

Frequently Asked Questions

What is the focus of BioStem Technologies?

BioStem Technologies specializes in developing placental-derived products for advanced wound care.

What is the BioREtain® technology?

BioREtain® is a proprietary processing method that preserves the natural properties of perinatal tissues for enhanced wound healing.

Where will the symposium take place?

The SAWC Spring meeting will be held in Dallas, Texas.

How can I learn more about BioStem products?

You can explore BioStem’s offerings by visiting their website or contacting their support team directly.

What partnership does BioStem have at the symposium?

BioStem is co-exhibiting with Venture Medical, emphasizing their collaborative efforts in wound care solutions.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 187

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 394

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
Sitting, Lymph Flow, and a Supplement Maker's Pitch

Updated Category News Views 182

By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 233

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading
ModuleMD Takes Allergy EHR AI Beyond the Usual Hype Cycle

Updated Category News Views 238

Allergy Workflows Are Where This Has to Earn Its Keep Allergy clinics do not need another shiny dashboard clogging up a workstation. They need less typing, fewer handoffs, cleaner documentation, and fewer administrative chores slipping through the cracks while a packed day keeps moving. That is the practical lens for ModuleMD's ACAAI 2026 presentation in Phoenix: not...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 183

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
Human Frontier Mission Puts AI Research on Display

Updated Category News Views 154

A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...

Continue Reading
Kinross Lawsuit Puts Round Mountain Claims Under Fire

Updated Category News Views 128

A mine can swallow a rosy forecast faster than any spreadsheet admits. That is the ugly center of the proposed securities class action involving Kinross Gold: not merely that production guidance came down, but the allegation that investors were sold too much confidence before the operational reality at Round Mountain Phase S surfaced. NYSE:KGC dropped from $27.62 on...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 168

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 217

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading

Top 5 Most Recently Viewed Articles

Allegations Against Symbotic Inc: The Investor Angle

Updated Category News Views 31

Allegations Rock Symbotic Inc. The ink is barely dry on the reports that some fat cats at Symbotic Inc. might've let their fingers get a bit too close to the cash till. There's a whirlwind brewing, pointing the finger squarely at the boardroom. Halper Sadeh LLC, the legal big shots known for scrutinizing shifty corporate moves, have thrown down the gauntlet, probing...

Continue Reading
David Lazar's Acquisition of Preferred Stock in Cyclacel

Updated Category News Views 210

Cyclacel Pharmaceuticals Engages Investor David Lazar for Preferred Stock Purchase Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP) has taken a notable step forward by entering into a strategic agreement with investor David Lazar for the acquisition of preferred stock. This agreement is heralding a new chapter in Cyclacel’s mission to develop innovative...

Continue Reading
TSC Alliance 50 Forward Fund Launches to Advance Research

Updated Category News Views 529

TSC Alliance Unveils 50 Forward Fund to Transform Research In a significant move aiming to revolutionize the lives of those affected by tuberous sclerosis complex (TSC), the TSC Alliance has launched the public phase of its 50 Forward Fund. This ambitious fundraising campaign is targeting a remarkable $40 million to drive forward research that promises to change the...

Continue Reading
What to Watch in the Stock Market Today - May 23, 2024

Updated Category Markets Views 359

Market Overview: Key Factors Influencing Stocks on May 23, 2024 Financial markets, especially the stock markets, are constantly fluctuating, and as it stands now, same for today, May 23, 2024. Market participants intend to deal for a number of earning calls, economic releases and geopolitical events that might turn the markets north or south. Thus, let’s go deeper into...

Continue Reading
Polish Stocks Surge as WIG30 Index Rises Significantly Today

Updated Category News Views 90

Positive Trends in Poland's Stock Market Today, the Polish stock market demonstrated a strong performance, with significant gains across multiple sectors as the day drew to a close. The WIG30 index, a prominent measure of stock performance in the nation, increased by 1.68%. This uplift was largely driven by growth in the Basic Materials, Construction, and Banking sectors....

Continue Reading